Fate Therapeutics (FATE) Jefferies 2024 Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies 2024 Global Healthcare Conference summary
8 Jul, 2026Industry landscape and therapeutic rationale
CAR T-cell therapy has shown remarkable results in small autoimmune patient cohorts, offering potential for drug-free remission and disease reset.
Current regimens require intensive conditioning and hospitalization, similar to oncology protocols, presenting challenges for autoimmune patients.
Off-the-shelf, iPSC-derived CAR T and CAR NK cell programs are being developed to improve patient access and treatment experience.
Clinical experience and product differentiation
The iPSC-derived CD19 CAR T construct has been used in 40-50 oncology patients, showing a 50% response rate, 25% CR rate, and strong safety profile.
Translational data demonstrate deep B-cell depletion in blood and tissue, with reconstitution of naive B cells, indicating immune reset potential.
The same construct, dose, and cell line are being used in the autoimmune lupus study.
Study design and operational strategy
The lupus phase I study leverages existing oncology sites and partnerships between oncologists and rheumatologists to facilitate enrollment.
Two sites (University of Minnesota and University of Nebraska Medical Center) are currently open, with more planned.
Site activation to first patient dosing took about eight weeks, and patients have already been dosed.
Latest events from Fate Therapeutics
- FT819 advances off-the-shelf CAR T into lupus nephritis and broader autoimmune care.FATE
Jefferies Global Healthcare Conference - $100 million Leerink ATM adds financing flexibility but carries material dilution risk.FATE
Registration filing - RECLAIM-LN advanced as management’s grant-inclusive runway outlook extended to mid-2028.FATE
Q3 2026 - Scalable CAR T platform shows strong safety, efficacy, and promising phase II progress in lupus nephritis.FATE
12th Annual Cantor Fitzgerald Global Healthcare Conference - Net loss narrowed, cash runway into 2028, and pivotal CAR T-cell trials advanced.FATE
Q2 2026 - FT819 and next-gen CAR T-cell therapies show strong clinical progress and financial stability.FATE
Corporate presentation - Net loss narrowed on lower expenses, with strong cash and key CAR T-cell advances, but risks remain.FATE
Q1 2026 - Key votes include director elections, auditor ratification, and incentive plan amendment.FATE
Proxy filing - Shareholders will vote on director elections, auditor ratification, say-on-pay, and equity plan expansion.FATE
Proxy filing